Skip to main content

JAK/TYK2

      #EULAR2021 and EULAR IQ
      Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

      https://t.co/

      Dr. John Cush RheumNow

      4 years 3 months ago
      #EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,

      Dr. John Cush RheumNow

      4 years 3 months ago
      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.
      RT @Janetbirdope: Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari &gt

      Janet Pope Janetbirdope

      4 years 3 months ago
      Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs (cont'd):
      *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
      🚫strong rec

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 3 months ago
      2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi*⃣Peri

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 3 months ago

      2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

      RT @doctorRBC: Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response⭐️HAQ-DI response⭐ï

      Robert B Chao, MD doctorRBC

      4 years 3 months ago

      Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

      RT @RichardPAConway: Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA

      Richard Conway RichardPAConway

      4 years 3 months ago
      Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
      RT @Janetbirdope: Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Be

      Janet Pope Janetbirdope

      4 years 3 months ago
      Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
      Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com Listen by Clicking below: 1. EULAR2021 - Day2a 2. EULAR2021 - Day2b
      RT @Janetbirdope: After 1st JAKi in RA would you use a 2nd #Jaki? @eular_org

      Janet Pope Janetbirdope

      4 years 3 months ago

      After 1st JAKi in RA would you use a 2nd #Jaki? @eular_org

      RT @Janetbirdope: JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy

      Janet Pope Janetbirdope

      4 years 3 months ago

      JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr

      RT @drdavidliew: Do you think that JAK1 selectivity matters in rheumatological clinical practice?#EULAR2021 @RheumNow

      David Liew drdavidliew

      4 years 3 months ago

      Do you think that JAK1 selectivity matters in rheumatological clinical practice? #EULAR2021 @RheumNow

      ×